07:00 , Oct 27, 2016 |  BC Innovations  |  Targets & Mechanisms

Cancer’s Phoenix

  Although recombinant IL-2 was a cancer immunotherapy long before checkpoint inhibitors came on the scene, the cytokine’s impact was limited by its potential for lethal side effects. Most attempts to lower toxicity also decreased efficacy....
08:00 , Jan 25, 2016 |  BC Week In Review  |  Clinical News

DI-Leu16-IL2: Phase I/II data

An open-label, dose-escalation, U.S. Phase I/II trial showed that thrice-weekly 0.5, 1 and 2 mg/m 2 subcutaneous DI-Leu16-IL2 every 3 weeks led to tumor regression or stabilization in 12 of 13 evaluable patients with relapsed...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Company News

Alopexx Enterprises LLC, Provenance deal

Alopexx and Provenance formed a JV to develop and commercialize Provenance's DI-Leu16-IL2. Provenance will contribute the compound and Alopexx will contribute $8 million to the JV, which will be named Alopexx Oncology LLC....